Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 11/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25118682 | 1.00 | CAPN1 (0.52) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL7346299 | 0.94 | CAPN1 (0.50) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL24221821 | 0.90 | KMT2A (0.53) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL22979065 | 0.88 | TDP1 (0.57) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL2946356 | 0.88 | TDP1 (0.57) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL1022916 | 0.85 | KMT2A (0.55) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL12056635 | 0.85 | CAPN1 (0.53) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL13165128 | 0.85 | TDP1 (0.58) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL13165125 | 0.85 | TDP1 (0.58) | CAPN1KMT2ACTSKCTSSMEN1 | |
| SCHEMBL3825056 | 0.85 | CAPN1 (0.53) | CAPN1KMT2ACTSKCTSSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-8835602-B2 | Templates for nucleation and propagation of peptide secondary structure | INDIAN INSTITUTE OF SCIENCE (IN) | 2014-09-16 | — | — | US | disclosed |
| US-20100228004-A1 | TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2010-09-09 | — | — | US | disclosed |
| EP-0126974-B1 | CARBOXYALKYL PEPTIDE DERIVATIVES | G.D. Searle & Co. (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4568666-A | COLLAGENASE INHIBITORS, ANTIARTJRITIC AGENTS | G. D. SEARLE & CO. (US) | 1986-02-04 | — | — | US | disclosed |
| US-4511504-A | COLLAGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1985-04-16 | — | — | US | disclosed |
| EP-0126974-A1 | Carboxyalkyl peptide derivatives | G.D. Searle & Co. (US) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228004-A1 | TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE | IAPP, NGLY1, HDGF | CAPN1 1848/4885KMT2A 4850/4885CTSK 1068/4885 |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | CAPN1 4679/4885KMT2A 919/4885CTSK 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.